# New York Ventures

> New York Ventures is a VC fund backing Health Care and Biotechnology. See 132 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 132
- Last investment: Jun 2026
- Lead investor: 6%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/empire-state-development/
- X (Twitter): https://twitter.com/EmpireStateDev
- Website: https://esd.ny.gov/venture-capital
- Facebook: https://www.facebook.com/EmpireStateDevelopment/

New York Ventures is a VC fund in New York focused on Health Care and Biotechnology. New York Ventures is dedicated to encouraging innovation and fueling economic growth in communities across the State. This venture capital investment arm of Empire State Development is one of New York State's business resources and innovation investments, including the Governor's START-UP NY program, Innovation Hot Spots, the RegionalEconomic Development Councils, the Centers of Advanced Technology and Centers of Excellence networks, and the SUNY 2020 Initiative.

## Contacts

5 contacts available for New York Ventures. Shizune tracks 2 team members at New York Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/new-york-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.5M–$7M |
| Series A | $3M–$20M |
| Series B | $2.5M–$53M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 20 | 15% |
| Biotechnology | 15 | 11% |
| Software | 12 | 9% |
| Medical | 9 | 7% |
| Manufacturing | 9 | 7% |

127 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 33 | 25% |
| Series A | 31 | 23% |
| Series B | 11 | 8% |
| Pre-Seed | 5 | 4% |
| Funding Round | 2 | 2% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 69 | 52% |
| Canada | 2 | 2% |
| Israel | 1 | 1% |
| Argentina | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Holly Sraeel | Founder & CEO, Content and Business Strategy Director / Journalist, Editorial Director, Speaker | 0 | https://shizune.co/investors/profile/holly-sraeel |
| Hope Knight | President, CEO and Commissioner | 4 | https://shizune.co/investors/profile/hope-knight-4464 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Fesarius Therapeutics | Fesarius Therapeutics is a biotechnology company that intends to develop and sell modified skin replacement products. To create a line of engineered tissue goods, developed a tissue engineering technique based on IP for microsphere-containing hydrogels. The company's method uses microspheres embedded in a collagen hydrogel to enhance thenumber of differential density interfaces that drive cell invasion into the scaffold, allowing patients to heal from trauma, burns, or infection at an affordable cost. | $20M | Series A | Jun 10, 2026 |  |
| CREW Carbon | CREW Carbon specializes in removing greenhouse gas emissions from wastewater using engineered enhanced weathering. The company's technology leverages the natural power of minerals to treat municipal and industrial wastewater, permanently storing CO2. CREW Carbon operates within the environmental services industry and focuses on GHG managementand carbon removal. The company aims to make a positive impact on the planet through innovative climate tech solutions. | $19M | Series A | May 14, 2026 |  |
| Fathom Therapeutics | Fathom Therapeutics, previously known as Atommap, is a biotechnology company focused on designing therapeutic molecules through computational drug discovery approaches. The company develops models that simulate biomolecular and protein motion to better understand how proteins behave and interact, enabling the identification of new therapeuticstrategies. Its platform combines generative design, predictive modeling, and computational assays to create and evaluate molecular candidates for their binding affinity and functional effects. By leveraging these simulations, it supports drug discovery processes such as hit identification, lead optimization, and the design of targeted molecules, including degraders and molecular glues. The company also collaborates with partners by providing molecular designs, predictive insights, and co-development opportunities for advancing therapeutic candidates. | $47M | Series A | Apr 27, 2026 |  |
| CryoBio | CryoBio is an agricultural biotech company that provides biological solutions that allow crops to withstand sub-zero temperatures without damage. | $1.3M | Pre-Seed | Feb 12, 2026 |  |
| Popwheels | PopWheels is an urban mobility company with a cutting-edge e-bike battery exchange network. | $2.3M | Seed | Dec 18, 2025 |  |
| Cayuga Biotech | Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayugais developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders. | $5M | Seed | Dec 11, 2025 |  |
| OncoPrecision | We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity and Resistance Test, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access toPrecision Oncology and improve cancer patients' lives. | $4.5M | Seed | Nov 24, 2025 |  |
| Nionyx Bio | Nionyx Bio builds AAV-based gene therapies to address some of the most potent kidney genetic diseases. | $4M | Seed | Sep 29, 2025 |  |
| Sharper Sense | Sharper Sense is a wearable patch that stimulates a nerve in the neck to enhance hearing, vision, and touch. This neuromodulation technology helps optimize sensory processing for improved perception. | $1.5M | Seed | Sep 01, 2025 |  |
| BQP | At BQP, we’re developing a quantum-accelerated digital twin platform for mission-critical applications. The platform, BQPhy, is a back-end engine that integrates seamlessly into existing engineering workflows and operates on today’s infrastructure without requiring quantum hardware. BQPhy helps teams solve large-scale, complex challenges inengineering optimization, data-driven modeling (ML), and physics-based (CFD) simulations. We are bridging the gap between current high-performance computers and future quantum systems with probabilistic algorithms from quantum information science, unlocking simulation capabilities that were previously impractical or impossible. BQPhy reduces time, accuracy, and throughput inefficiencies, thereby accelerating development cycles, unlocking previously unexplored design spaces, lowering costs, and enhancing product outcomes. | $4.9M | Seed | Jul 17, 2025 |  |

10 of 132 investments shown.

## Co-investors
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund, 5 deals together
- [Gaingels](https://shizune.co/investors/profile/gaing) — VC Fund, 5 deals together
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 5 deals together
- [Creative Ventures](https://shizune.co/investors/profile/creative-ventures) — VC Fund, 4 deals together
- [Launch NY](https://shizune.co/investors/profile/launch-ny) — VC Fund, 4 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Climate Investors in United States](https://shizune.co/investors/climate-investors-united-states)
- [Climate VC Funds in United States](https://shizune.co/investors/climate-vc-funds-united-states)
- [Energy Investors in United States](https://shizune.co/investors/energy-investors-united-states)
- [Energy VC Funds in United States](https://shizune.co/investors/energy-vc-funds-united-states)
- [Sustainability Investors in United States](https://shizune.co/investors/sustainability-investors-united-states)
- [Sustainability VC Funds in United States](https://shizune.co/investors/sustainability-vc-funds-united-states)

## FAQ

### What does New York Ventures invest in?

New York Ventures invests primarily in Health Care, Biotechnology and Software startups, most often at Seed and Series A stage. Most of the 132 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is New York Ventures's check size?

New York Ventures typically joins rounds of $1.5M–$7M at Seed, $3M–$20M at Series A and $2.5M–$53M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds New York Ventures participates in.

### How do I contact New York Ventures?

Public channels for New York Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at New York Ventures?

The team at New York Ventures includes Holly Sraeel (Founder & CEO, Content and Business Strategy Director / Journalist, Editorial Director, Speaker) and Hope Knight (President, CEO and Commissioner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co